Advances and challenges: dendritic cell vaccination strategies for glioblastoma
Introduction: Glioblastoma is the most common primary brain tumor in adults and prognosis remains poor with a median survival of approximately 15–17 months. This review provides an overview of recent advances in the field of glioblastoma immunotherapy. Areas covered: Recent advances in dendritic cel...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-01-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2016.1218762 |
| _version_ | 1797680422630457344 |
|---|---|
| author | Teilo H. Schaller John H. Sampson |
| author_facet | Teilo H. Schaller John H. Sampson |
| author_sort | Teilo H. Schaller |
| collection | DOAJ |
| description | Introduction: Glioblastoma is the most common primary brain tumor in adults and prognosis remains poor with a median survival of approximately 15–17 months. This review provides an overview of recent advances in the field of glioblastoma immunotherapy. Areas covered: Recent advances in dendritic cell vaccination immunotherapy are showing encouraging results in clinical trials and promise to extend patient survival. In this report we discuss current scientific knowledge regarding dendritic cell (DC) vaccines, including approaches to differentiating, priming, and injecting dendritic cells to achieve maximal anti-tumor efficacy in glioblastoma. These findings are compared to recently completed and currently ongoing glioblastoma clinical trials. Novel methods such as ‘fastDCs’ and vaccines targeting DCs in-vivo may offer more effective treatment when compared to traditional DC vaccines and have already entered the clinic. Expert commentary: Finally, we discuss the challenges of T-cell dysfunctions caused by glioblastoma immunosuppression and how they affect dendritic cell vaccinations approaches. |
| first_indexed | 2024-03-11T23:29:48Z |
| format | Article |
| id | doaj.art-74e514cb0d6746b99ef8c7ac18825765 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:29:48Z |
| publishDate | 2017-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-74e514cb0d6746b99ef8c7ac188257652023-09-20T10:18:01ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952017-01-01161273610.1080/14760584.2016.12187621218762Advances and challenges: dendritic cell vaccination strategies for glioblastomaTeilo H. Schaller0John H. Sampson1Duke University Medical CenterDuke University Medical CenterIntroduction: Glioblastoma is the most common primary brain tumor in adults and prognosis remains poor with a median survival of approximately 15–17 months. This review provides an overview of recent advances in the field of glioblastoma immunotherapy. Areas covered: Recent advances in dendritic cell vaccination immunotherapy are showing encouraging results in clinical trials and promise to extend patient survival. In this report we discuss current scientific knowledge regarding dendritic cell (DC) vaccines, including approaches to differentiating, priming, and injecting dendritic cells to achieve maximal anti-tumor efficacy in glioblastoma. These findings are compared to recently completed and currently ongoing glioblastoma clinical trials. Novel methods such as ‘fastDCs’ and vaccines targeting DCs in-vivo may offer more effective treatment when compared to traditional DC vaccines and have already entered the clinic. Expert commentary: Finally, we discuss the challenges of T-cell dysfunctions caused by glioblastoma immunosuppression and how they affect dendritic cell vaccinations approaches.http://dx.doi.org/10.1080/14760584.2016.1218762glioblastomacancer vaccinedendritic cellimmunotherapyclinical trialsimmunosuppressiont-cell dysfunctionfastdcsin-vivo dc vaccinerecall antigens |
| spellingShingle | Teilo H. Schaller John H. Sampson Advances and challenges: dendritic cell vaccination strategies for glioblastoma Expert Review of Vaccines glioblastoma cancer vaccine dendritic cell immunotherapy clinical trials immunosuppression t-cell dysfunction fastdcs in-vivo dc vaccine recall antigens |
| title | Advances and challenges: dendritic cell vaccination strategies for glioblastoma |
| title_full | Advances and challenges: dendritic cell vaccination strategies for glioblastoma |
| title_fullStr | Advances and challenges: dendritic cell vaccination strategies for glioblastoma |
| title_full_unstemmed | Advances and challenges: dendritic cell vaccination strategies for glioblastoma |
| title_short | Advances and challenges: dendritic cell vaccination strategies for glioblastoma |
| title_sort | advances and challenges dendritic cell vaccination strategies for glioblastoma |
| topic | glioblastoma cancer vaccine dendritic cell immunotherapy clinical trials immunosuppression t-cell dysfunction fastdcs in-vivo dc vaccine recall antigens |
| url | http://dx.doi.org/10.1080/14760584.2016.1218762 |
| work_keys_str_mv | AT teilohschaller advancesandchallengesdendriticcellvaccinationstrategiesforglioblastoma AT johnhsampson advancesandchallengesdendriticcellvaccinationstrategiesforglioblastoma |